Lavigne Jérémy, Soysouvanh Frédéric, Buard Valérie, Tarlet Georges, Guipaud Olivier, Paget Vincent, Milliat Fabien, François Agnès
Radiobiology and Radiopathology Research Laboratory, Department of Radiobiology and Epidemiology, Institute for Radiological Protection and Nuclear Safety, Fontenay-aux-Roses, France.
Radiobiology and Radiopathology Research Laboratory, Department of Radiobiology and Epidemiology, Institute for Radiological Protection and Nuclear Safety, Fontenay-aux-Roses, France.
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):972-982. doi: 10.1016/j.ijrobp.2017.07.007. Epub 2017 Jul 11.
To investigate whether the endothelial pool of plasminogen activator inhibitor type 1 (PAI-1) plays a role in the development of radiation-induced lung damage, as previously demonstrated in the intestine.
Human lung microvascular endothelial cells were exposed to 10 Gy irradiation so as to study their ability to acquire an "activated" phenotype. Mice in which the Cre-Lox strategy was used to produce PAI-1 deletion specifically in the endothelial compartment were exposed to 17 Gy whole-thorax irradiation and followed up for 2, 13, and 23 weeks after irradiation.
Human lung microvascular endothelial cells had an activated phenotype after radiation exposure, overexpressed PAI-1, and underwent endothelial-to-mesenchymal transition. In mice, knockout of PAI-1 in the endothelium had no beneficial effect on radiation-induced lung damage and showed a tendency to worsen acute lesions.
As opposed to the intestine, the endothelial pool of PAI-1 does not play a determinant role in the development of radiation-induced lung damage. The therapeutic value of PAI-1 inhibition in lung radiation injury may be associated with other types of cells.
如先前在肠道中所证实的那样,研究纤溶酶原激活物抑制剂1(PAI-1)的内皮细胞池是否在放射性肺损伤的发生发展中起作用。
将人肺微血管内皮细胞暴露于10 Gy辐射下,以研究其获得“活化”表型的能力。使用Cre-Lox策略在血管内皮细胞中特异性敲除PAI-1的小鼠接受17 Gy全胸照射,并在照射后2、13和23周进行随访。
人肺微血管内皮细胞在辐射暴露后具有活化表型,PAI-1表达上调,并发生内皮-间充质转化。在小鼠中,内皮细胞中PAI-1的敲除对放射性肺损伤没有有益作用,并且显示出急性损伤恶化的趋势。
与肠道不同,PAI-1的内皮细胞池在放射性肺损伤的发生发展中不起决定性作用。PAI-1抑制在肺部放射性损伤中的治疗价值可能与其他类型的细胞有关。